26 recruiting, 5 not yet recruiting, 3 active not recruiting. 34 Phase 2, 8 Phase 3, 2 Phase 1.
By phase and status
Follow Iza-bren: new trials by email Literature Review of Iza-bren trials Research Report on Iza-bren
Trials (filtered) newest first · largest first
All 34 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | 166 | 2026-11-01 | 2026-10-28 |
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
BL-B01D1, PD-1 monoclonal antibody, Gemcitabine - Nasopharyngeal Carcinoma (NPC) | Phase 2 | Not yet recruiting | 60 | 2026-09-01 | 2026-09-16 |
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BL-B01D1, Glecirasib - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | 36 | 2026-09-01 | 2026-09-18 |
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | 180 | 2026-09-01 | 2026-07-23 |
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
BL-B01D1, PD-1/VEGF bispecific antibody, Paclitaxel - Squamous Non-small-cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | 200 | 2026-08-01 | 2026-08-26 |
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
BL-B01D1, Osimertinib, Carboplatin - Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | 90 | 2026-07-24 | 2026-08-03 |
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
BL-B01D1, Tislelizumab, 5-Fluorouracil - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | 90 | 2026-06-09 | 2026-07-16 |
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Iza-bren, Carboplatin, Cisplatin - Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | 500 | 2025-11-05 | 2026-10-09 |
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Iza-bren, Cisplatin, Gemcitabine - Urothelial Cancer | Phase 2 / Phase 3 | Recruiting | 470 | 2025-09-30 | 2026-07-29 |
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Iza-bren, Nab-paclitaxel, Paclitaxel - Breast Neoplasms | Phase 2 / Phase 3 | Recruiting | 600 | 2025-09-11 | 2026-08-10 |
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
BMS-986504, Izalontamab Brengitecan - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | 182 | 2025-09-09 | 2026-09-18 |
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
BL-B01D1, Pembrolizumab, Bevacizumab - Cervical Cancer, Endometrial Cancer | Phase 2 | Recruiting | 96 | 2025-08-21 | 2026-01-21 |
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
BL-B01D1, Axitinib, Lenvatinib - Renal Cancer | Phase 2 | Recruiting | 260 | 2025-07-28 | 2025-11-17 |
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
BL-B01D1, Lenvatinib, Finotonlimab - Advanced Hepatocellular Carcinoma | Phase 2 | Recruiting | 74 | 2025-06-24 | 2026-06-10 |
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
BL-B01D1, Pembrolizumab - Advanced Biliary Tract Cancer | Phase 2 | Recruiting | 46 | 2025-06-10 | 2025-07-02 |
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
BMS-986507, Osimertinib, Pembrolizumab - Lung Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | 416 | 2025-02-04 | 2026-09-23 |
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
BL-B01D1 - Chordoma | Phase 2 | Active not recruiting | 27 | 2025-01-16 | 2026-04-13 |
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
BL-B01D1 for Injection - Recurrent Glioblastoma | Phase 2 | Recruiting | 20 | 2024-10-17 | 2025-05-07 |
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
BL-B01D1, PD-1 Monoclonal Antibody - Triple-negative Breast Cancer | Phase 2 | Recruiting | 52 | 2024-08-02 | 2026-07-23 |
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
BL-B01D1, Osimertinib Mesylate Tablets - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | 76 | 2024-07-31 | 2026-10-09 |
Showing 20 of 34. Sign in to see all of them.
Conditions studied
Carcinoma, Non-Small-Cell Lung (9) · Breast Neoplasms (3) · Nasopharyngeal Carcinoma (3) · Triple Negative Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Transitional Cell (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Small Cell Lung Carcinoma (2) · Squamous Cell Carcinoma of Head and Neck (2) · Chordoma (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Glioblastoma (1)
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd. (29) · Bristol-Myers Squibb (5)
Countries
China (33) · France (5) · Italy (5) · Spain (5) · United Kingdom (5) · United States (5) · Australia (4) · Canada (4) · Germany (4) · Japan (4) · Romania (4) · Argentina (3) · Chile (3) · Netherlands (3) · Poland (3)
Top investigators
Caicun Zhou, PHD (2) · Chaosu Hu (2) · Dingwei Ye, PHD (2) · Dongmei Ji (2) · Jian Zhang, PHD (2) · Caicun Zhou (1) · Dingwei Ye (1) · Jian Zhang (1) · Jiong Wu (1) · Jiong Wu, PHD (1) · Li Zhang (1) · Li Zhang, PHD (1) · Lin Shen (1) · Lingying Wu, PHD (1)
Results publications
PMID 41611210